MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Introduction: Mononuclear phagocytes play a critical role during Alzheimer's disease (AD) pathogenesis due to their contribution to innate immune responses and amyloid beta (Aβ) clearance mechanisms. Methods: Blood‐derived monocytes (BDMs) and monocyte‐derived macrophages (MDMs) were isolated from blood of AD, mild cognitive impairment (MCI) patients, and age‐matched healthy controls for molecular and phenotypic comparisons. Results: The chemokine/chemokine receptor CCL2/CCR2 axis was impaired in BDMs from AD and MCI patients, causing a deficit in cell migration. Changes were also observed in MDM‐mediated phagocytosis of Aβ fibrils, correlating with alterations in the expression and processing of the triggering receptor expressed on myeloid cells 2 (TREM2). Finally, immune‐related microRNAs (miRNAs), including miR‐155, ‐154, ‐200b, ‐27b, and ‐128, were found to be differentially expressed in these cells. Discussion: This work provides evidence that chemotaxis and phagocytosis, two crucial innate immune functions, are impaired in AD and MCI patients. Correlations with miRNA levels suggest an epigenetic contribution to systemic immune dysfunction in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“expression of chemokine receptors, such as CCR2, which mediate BDM migration and infiltration into the brain parenchyma [4,5] and phagocytosis-related proteins, such as the new AD risk protein, triggering receptor expressed on myeloid cells 2 (TREM2) [6].”
BackgroundGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 2×
“Interestingly, we also found that eight of the new AD susceptibility genes (CR1, BIN1, PICALM, SORL1, MS4A4A, CD33, CD2AP, and CLU) [30–32] are predicted targets of at least one miRNA shown to be differentially expressed (Supplementary Table 2) and can potentially be regulated by miR-154, -27b, -200b, -128, and -155.”
BackgroundEl Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798 · cited 6×
“Although the R47H TREM2 mutation was absent in our cohort, the fact that TREM2 has been implicated in the regulation of phagocytic activity [15] led us to explore the expression profile of TREM2 in BDMs and MDMs from AD and MCI patients.”
BackgroundMethodResultInfluentialJay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142322 · Cited by 682
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS
Butovsky, O., Siddiqui, S., Gabriely, G., Lanser, A. J., Dake, B., Murugaiyan, G., Doykan, C. E., Wu, P. M., Gali, R. R., Iyer, L. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62636 · Cited by 481
Krabbe, G., Halle, A., Matyash, V., Rinnenthal, J. L., Eom, G. D., Bernhardt, U., Miller, K. R., Prokop, S., Kettenmann, H., & Heppner, F. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060921 · Cited by 478 · cited 1×
“Deficiencies in microglia-mediated Ab phagocytosis have also been reported in AD [43], suggesting that microglia lose their ability to clear Ab deposits with age and disease.”
BackgroundCardoso, A. L., Guedes, J. R., Pereira de Almeida, L., & Pedroso de Lima, M. C. (2012) · Immunology · doi:10.1111/j.1365-2567.2011.03514.x · Cited by 336
Self-citationWunderlich, P., Glebov, K., Kemmerling, N., Tien, N. T., Neumann, H., & Walter, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.517540 · Cited by 296
Real-Time In Vivo Imaging Reveals the Ability of Monocytes to Clear Vascular Amyloid Beta
Michaud, J.-P., Bellavance, M.-A., Préfontaine, P., & Rivest, S. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.010 · Cited by 257
Resende, R., Ferreiro, E., Pereira, C., & Resende de Oliveira, C. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.06.036 · Cited by 235
Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease
Galimberti, D., Fenoglio, C., Lovati, C., Venturelli, E., Guidi, I., Corrà, B., Scalabrini, D., Clerici, F., Mariani, C., Bresolin, N., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.007 · Cited by 209 · cited 1×
“Moreover, because chemokine receptors exert a scavenging role by binding and removing chemokines from circulation and tissues [38], the reduction of CCR2(1) BDMs can contribute to the increased levels of CCL2 observed in the serum of AD patients [39].”
BackgroundNaert, G., & Rivest, S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0299-11.2011 · Cited by 207 · cited 1×
“Deficiency in CCR2 in the Tg2576 and APPSwe/PS1 mice exacerbated amyloidosis [4,8], whereas transplantation of CCR2competent cells into APPSwe/PS1/CCR2 2/2 restored cognitive functions [5].”
BackgroundMigration of neutrophils targeting amyloid plaques in Alzheimer's disease mouse model
Baik, S. H., Cha, M.-Y., Hyun, Y.-M., Cho, H., Hamza, B., Kim, D. K., Han, S.-H., Choi, H., Kim, K. H., Moon, M., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.003 · Cited by 181 · cited 1×
“Although previous in vitro studies have suggested that Ab soluble monomers do not act as a direct chemoattractant for immune cells [29], it is believed that monocytes can potentially bind to vascular Ab deposits in brain vessels [2].”
BackgroundGuedes, J. R., Custódia, C. M., Silva, R. J., de Almeida, L. P., Pedroso de Lima, M. C., & Cardoso, A. L. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu348 · Cited by 170
Self-citationTiribuzi, R., Crispoltoni, L., Porcellati, S., Di Lullo, M., Florenzano, F., Pirro, M., Bagaglia, F., Kawarai, T., Zampolini, M., Orlacchio, A., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.003 · Cited by 162
Integrated expression profiles of mRNA and miRNA in polarized primary murine microglia
Freilich, R. W., Woodbury, M. E., & Ikezu, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079416 · Cited by 160
Koronyo, Y., Salumbides, B. C., Sheyn, J., Pelissier, L., Li, S., Ljubimov, V., Moyseyev, M., Daley, D., Fuchs, D.-T., Pham, M., et al. (2015) · Brain · doi:10.1093/brain/awv150 · Cited by 153
A deficiency in CCR2+ monocytes: the hidden side of Alzheimer’s disease
Naert, G., & Rivest, S. (2013) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt028 · Cited by 123
Pellicanò, M., Bulati, M., Buffa, S., Barbagallo, M., Di Prima, A., Misiano, G., Picone, P., Di Carlo, M., Nuzzo, D., Candore, G., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091714 · Cited by 86
Cited by
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
“Research has identified miRNAs that contribute to Aβ-induced neurotoxicity [228], synaptic dysfunction [229], immune reactions [230], and tau pathogenesis [231].”
BackgroundMicroRNAs in Alzheimer’s Disease
Wang, M., Qin, L., & Tang, B. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00153 · Cited by 307
Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders
van den Berg, M. M. J., Krauskopf, J., Ramaekers, J. G., Kleinjans, J. C. S., Prickaerts, J., & Briedé, J. J. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101732 · Cited by 253
MiR-155: An Important Regulator of Neuroinflammation
Zingale, V. D., Gugliandolo, A., & Mazzon, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010090 · Cited by 163
The Future of Precision Medicine in the Cure of Alzheimer’s Disease
Arafah, A., Khatoon, S., Rasool, I., Khan, A., Rather, M. A., Abujabal, K. A., Faqih, Y. A. H., Rashid, H., Rashid, S. M., Bilal Ahmad, S., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020335 · Cited by 133
Metadata
- Authors
- Guedes, J. R., Santana, I., Cunha, C., Duro, D., Almeida, M. R., Cardoso, A. M., de Lima, M. C. P., & Cardoso, A. L.
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2015-12-12
- Volume
- 3
- Issue
- 1
- Pages
- 7-17
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W2221703732
- Cited by
- 76
- References
- 23
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.